Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Low Oxygen Levels, Poor Exercise Endurance Are Common

Low oxygen levels during sleep and while exercising — resulting in poor endurance — are very common among Parkinson’s disease patients, despite dopaminergic treatment, an Italian study suggests. The findings indicate a need for combining motor and respiratory rehabilitation, particularly for patients with severe Parkinson’s, who show the lowest…

Supernus Boosts Therapy Portfolio With Finalized Buyout of Adamas

Supernus Pharmaceuticals’ portfolio of Parkinson’s disease therapies now includes Gocovri (amantadine) and Osmolex ER (amantadine hydrochloride), with the company’s acquisition of Adamas Pharmaceuticals now complete. “Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue,” Jack Khattar, president and CEO of Supernus…

Cala Health Raises $77M for Bioelectronic Devices for Tremors

Cala Health has raised $77 million that will support further innovations of the company’s expertise — bioelectronic medicine — to explore conditions beyond essential tremor, including Parkinson’s disease and other neurological conditions. The funding also will help expand patient access to the company’s devices, which includes Cala Trio, a…

STAR Molecule to Restore GCase Activity Showing Early Potential

An oral candidate therapy for Parkinson’s disease called GT-02287 lowered the levels of alpha-synuclein accumulation and inflammation, and lessened behavioral deficits in animal models of the disease. “We are working diligently to advance this breakthrough compound to the clinic and bring it one step closer to meeting the currently unaddressed needs…

Nouryant Again Denied Marketing Approval in Europe

A committee of the European Medicines Agency (EMA) has issued a negative opinion for Nouryant (istradefylline) — approved as Nourianz in the U.S. — as an add-on medication for treating “off” episodes in those with Parkinson’s disease in the European Union. The Committee for Medicinal Products for Human Use (CHMP) is maintaining…

Lessening Dyskinesia With Duodopa Linked to Better Quality of Life

By lessening the involuntary movements, called dyskinesia, experienced by people with advanced Parkinson’s disease, treatment with AbbVie’s Duodopa (levodopa-carbidopa intestinal gel) was linked with better health-related quality of life, according to a post-hoc analysis of a clinical trial. Duodopa treatment also was tied to other added benefits, namely…